

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## INTERVENTIONAL PROCEDURES PROGRAMME

### Equality impact assessment

#### IPG659 low energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

#### Briefing

1. Have any potential equality issues been identified during the briefing process (development of the brief or discussion at the committee meeting), and, if so, what are they?

**Age:** Occurrence of colorectal cancer is strongly related to age, with almost three-quarters of cases occurring in people aged 50 or over.

**Gender:** The incidence of rectal cancer in the UK is approximately 29 per 100 000 males and 17 per 100,000 females.

**Ethnicity:** Rates for Asian and Black males are significantly lower than those for White males, and there is a similar pattern for females.

**Disability:** All people with cancer are covered by under disability n of the Equality Act 2010 from the point of diagnosis.

**Socioeconomic status:** There is evidence for a small association between bowel cancer incidence and deprivation for males in England, while there is no evidence of an association for females. England-wide data for 2006-2010 show European age-standardised incidence rates are 13% higher for males living in the most deprived areas compared with the least deprived, while for females the rates are similar for those living in the least and most deprived areas.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? (If there are exclusions listed in the brief (for example, populations, treatments or settings), are these justified?)

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.

3. Has any change to the brief (such as additional issues raised during the committee meeting) been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?

No

**Kevin Harris**

**Approved by Programme Director and Clinical Advisor for IP**

**Date:** 02/07/2019

## **Consultation**

1. Have the potential equality issues identified during the briefing process been addressed by the committee, and, if so, how?

No specific data relating to [potential issues mentioned earlier] was identified in the literature presented in the overview.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?
Not applicable

7. Have the committee's considerations of equality issues been described in the consultation document, and, if so, where?
No

**Kevin Harris**

**Approved by Programme Director and Clinical Advisor for IP**

**Date:** 02/07/2019

### **Final interventional procedures document**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access

identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

5. Have the committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?
No

**Mirella Marlow**

**Approved by Programme Director**

**Date:** 12 July 2019